Fig. 16
From: First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
OS(NI-N) derived from the model simulation
Fig. 16 | Orphanet Journal of Rare Diseases
From: First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
OS(NI-N) derived from the model simulation
Orphanet Journal of Rare Diseases